ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops its product candidates using its Targeted Antibody Payload (TAP) technology.
ImmunoGen Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.